Active not recruitingPHASE2INTERVENTIONAL

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

At a glance

Status

Active not recruiting

Phase

PHASE2

Sponsor

Acerta Pharma BV

Enrolment target

124

Start

02 Mar 2015

Estimated completion

06 Sep 2026

Mantle Cell Lymphoma (MCL)

What is this study about?

The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).

Who may be eligible?

Age 18 Years to any · Sex: ALL

Locations (58)

Research Site
Tampa, United States
Research Site
Chicago, United States
Research Site
Niles, United States
Research Site
Peoria, United States
Research Site
Boston, United States
Research Site
Hackensack, United States
Research Site
New York, United States
Research Site
Houston, United States
Research Site
Seattle, United States
Research Site
Monash, Australia
Research Site
Sydney, Australia
Research Site
Wodonga, Australia

+46 more sites — see the official record for the full list.

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.